- Trials with a EudraCT protocol (352)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
352 result(s) found for: First impression.
Displaying page 6 of 18.
| EudraCT Number: 2021-001010-10 | Sponsor Protocol Number: CGT9486-20-201 | Start Date*: 2021-12-09 | |||||||||||
| Sponsor Name:Cogent Biosciences, Inc. | |||||||||||||
| Full Title: A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis | |||||||||||||
| Medical condition: Advanced Systemic Mastocytosis (AdvSM) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) DE (Trial now transitioned) NO (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-001876-21 | Sponsor Protocol Number: ACT11917 | Start Date*: 2011-11-22 | |||||||||||
| Sponsor Name:sanofi-aventis recherche et développement | |||||||||||||
| Full Title: MULTINATIONAL, MULTICENTER, RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF EFFICACY AND SAFETY OF SAR292833 ADMINISTRATION FOR 4 WEEKS IN PATIENTS WITH CHRONIC PERIPHERAL NEUR... | |||||||||||||
| Medical condition: Neuropathic pain | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) CZ (Completed) SK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-023043-15 | Sponsor Protocol Number: MRZ60201/SP/3001 | Start Date*: 2011-09-14 | |||||||||||
| Sponsor Name:Merz Pharmaceuticals GmbH | |||||||||||||
| Full Title: Prospective, double-blind, placebo-controlled, randomized, multi-center study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of post-stroke sp... | |||||||||||||
| Medical condition: post-stroke spasticity of the upper limb | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) HU (Completed) CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-004255-38 | Sponsor Protocol Number: cnp-MS-0601/MC-2006-01 | Start Date*: 2007-01-05 | |||||||||||
| Sponsor Name:Bionorica research GmbH | |||||||||||||
| Full Title: Multi-centre, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of the pain relieving effect of Dronabinol in patients with multiple sclerosis associated wit... | |||||||||||||
| Medical condition: Patients with multiple sclerosis associated with central neuropathic pain | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) DK (Prematurely Ended) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001176-15 | Sponsor Protocol Number: BIA-91067-405 | Start Date*: 2021-05-07 | |||||||||||
| Sponsor Name:Bial - Portela & Ca, S.A. | |||||||||||||
| Full Title: Open-label, single-arm, pilot study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated sleep disorders. | |||||||||||||
| Medical condition: Parkinson's disease patients with wearing-off motor fluctuations and associated sleep disorders. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) PT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-003990-17 | Sponsor Protocol Number: 54135419SUI3001 | Start Date*: 2017-05-18 | ||||||||||||||||||||||||||
| Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||||||||||||
| Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Sympto... | ||||||||||||||||||||||||||||
| Medical condition: Major Depressive Disorder with Imminent Risk of Suicide | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: SK (Completed) DE (Completed) HU (Completed) ES (Completed) BG (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2018-001619-65 | Sponsor Protocol Number: TV46000-CNS-30072 | Start Date*: 2018-11-14 | |||||||||||
| Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
| Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneou... | |||||||||||||
| Medical condition: Maintenance treatment of schizophrenia in patients currently treated with oral antipsychotics | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-003094-61 | Sponsor Protocol Number: GWEP20238 | Start Date*: 2022-09-26 | |||||||||||
| Sponsor Name:GW RESEARCH LTD. | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled, multisite, Phase 3 study to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-P) in children and adolescents with epilepsy w... | |||||||||||||
| Medical condition: Epilepsy with myoclonic-atonic seizures | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-001389-93 | Sponsor Protocol Number: 13-005 | Start Date*: 2015-08-27 | |||||||||||
| Sponsor Name:Jazz Pharmaceuticals | |||||||||||||
| Full Title: A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of Xyrem with an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Su... | |||||||||||||
| Medical condition: Narcolepsy with Cataplexy | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) NL (Completed) IT (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-004405-64 | Sponsor Protocol Number: MT-2-03 | Start Date*: 2019-03-07 | |||||||||||
| Sponsor Name:Minoryx Therapeutics BE, SA | |||||||||||||
| Full Title: A Double-Blind, Placebo-Controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological, and Clinical Markers in Patients with Friedreich’s Ataxia | |||||||||||||
| Medical condition: Friedreich’s Ataxia | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) FR (Completed) DE (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-000422-16 | Sponsor Protocol Number: UCAB-CT-05 | Start Date*: 2022-07-26 | |||||||||||
| Sponsor Name:Umecrine Cognition AB | |||||||||||||
| Full Title: A randomised, double-blind, placebo-controlled, two-part study to evaluate the pharmacokinetics, safety and tolerability, and preliminary efficacy of two dose levels of golexanolone in subjects wit... | |||||||||||||
| Medical condition: Primary biliary cholangitis (PBC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-022873-32 | Sponsor Protocol Number: MRK008b-2010 | Start Date*: 2010-12-14 |
| Sponsor Name:Analgesic Solutions | ||
| Full Title: An Enriched Enrollment, Double Blind, Placebo-Controlled, Parallel Group, Randomized Withdrawal Trial to Evaluate the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients with Mode... | ||
| Medical condition: Patients with Neuropathic Pain. In the first instance, the investigator will aim to recruit patients with post herpetic neuralgia. If insufficient patients with post herpetic neuralgia are recruite... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-000970-31 | Sponsor Protocol Number: TUD-ASLith-057 | Start Date*: 2013-11-27 | |||||||||||
| Sponsor Name:Technische Universität Dresden | |||||||||||||
| Full Title: Randomized, placebo-controlled multicenter trial of lithium plus treatment as usual (TAU) for acute suicidal ideation and behaviour in patients with suicidal major depressive episode | |||||||||||||
| Medical condition: Diagnosis of a major depressive episode; inpatient at screening visit; suicidal ideation/behaviour present defined by a clinical rating of ≥ 8 on the Sheehan Suicidality Tracking Scale (S-STS) at... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-000444-84 | Sponsor Protocol Number: EMR62225-030 | Start Date*: 2005-06-22 |
| Sponsor Name:Merck KGaA | ||
| Full Title: An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from... | ||
| Medical condition: Treatment-Associated Dyskinesia in Parkinson's Disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Prematurely Ended) FI (Prematurely Ended) GB (Completed) IT (Prematurely Ended) ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-002484-25 | Sponsor Protocol Number: TAK-935-2002(OV935) | Start Date*: 2019-04-29 |
| Sponsor Name:Takeda Development Center Americas, Inc. | ||
| Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-935 (OV935) AS AN ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS WITH ... | ||
| Medical condition: Epileptic Encephalitis: Dravet and Lennox Gastuat syndrome (LGS) | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: PT (Completed) PL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-002876-25 | Sponsor Protocol Number: 178-CL-206A | Start Date*: 2016-03-30 | ||||||||||||||||
| Sponsor Name:Astellas Pharma Europe B.V. | ||||||||||||||||||
| Full Title: An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children... | ||||||||||||||||||
| Medical condition: Neurogenic detrusor overactivity (NDO) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Completed) LT (Completed) NO (Completed) BE (Completed) SK (Completed) RO (Completed) LV (Completed) HR (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2017-002263-17 | Sponsor Protocol Number: BRN-C-2017-01 | Start Date*: 2017-11-02 | |||||||||||
| Sponsor Name:BOIRON | |||||||||||||
| Full Title: Efficacy and safety of Passiflora Compose in patients newly diagnosed with adjustment disorder with anxiety, as first-line treatment, compared to alprazolam | |||||||||||||
| Medical condition: Adjustment disorder with anxiety | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-001311-79 | Sponsor Protocol Number: JZP080-301 | Start Date*: 2019-01-09 | ||||||||||||||||
| Sponsor Name:Jazz Pharmaceuticals | ||||||||||||||||||
| Full Title: A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) with an Open-label Safety Extension | ||||||||||||||||||
| Medical condition: Treatment of Idiopathic Hypersomnia | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) DE (Completed) ES (Completed) FI (Completed) IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2022-001611-50 | Sponsor Protocol Number: S67072 | Start Date*: 2022-11-15 | |||||||||||
| Sponsor Name:UZ Leuven | |||||||||||||
| Full Title: Patient reported efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease | |||||||||||||
| Medical condition: Aspirin-Exacerbated Respiratory Disease (AERD) in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-002113-19 | Sponsor Protocol Number: 42756493CAN2002 | Start Date*: 2019-10-31 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations | |||||||||||||
| Medical condition: Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations. | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) DE (Trial now transitioned) ES (Ongoing) BE (Completed) IT (Completed) Outside EU/EEA SE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.